Acrivon Therapeutics (ACRV) Opens Up 7%

Today's IPO for Acrivon Therapeutics, Inc. (Nasdaq: ACRV) opened for trading at $13.35 after pricing 7,550,000 shares of common stock at a public offering price of $12.50 per share.

Jefferies, Cowen and Piper Sandler acted as joint lead book-running managers for the offering.

Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.

You May Also Be Interested In

• Jersey Mike's launches IPO roadshow, targets NYSE listing as JMKE
• AlTi Global hires senior advisor to lead its Miami office
• Jersey Mike’s Subs targets up to $1.09 billion raise in US IPO